Achillion Pharmaceuticals, Inc. today announced the nomination of the preclinical compound, ACH-3422, a novel small molecule nucleotide prodrug of a uridine analog designed to inhibit HCV NS5B polymerase.
http://www.drugs.com/clinical_trials/achillion-nominates-ach-3422-nucleotide-chronic-hcv-15620.html?
http://www.drugs.com/clinical_trials/achillion-nominates-ach-3422-nucleotide-chronic-hcv-15620.html?
No comments:
Post a Comment